Australian STI Management Guidelines for Use in Primary Care

People in custodial settings

Overview

- People in custodial settings are often from marginalised and disproportionally criminalised groups, including <u>Aboriginal and Torres Strait</u> <u>Islander people</u>, <u>people who use drugs</u>, <u>sex workers</u>, <u>trans and gender</u> <u>diverse people</u>, and people from <u>culturally and linguistically diverse (CALD)</u> <u>backgrounds</u>.
- <u>Injecting drug use</u> and unsafe tattooing occur in custodial settings. Given the lack of appropriate and accessible harm reduction measures, incarceration is a risk factor for blood borne virus (BBV) infection and sexually transmitted infection (<u>STI</u>) transmission.
- Unwanted sex, including <u>sexual assault</u>, can occur in custodial settings; additionally people may engage in different sexual practices (prison sex, including <u>sex between men</u>) from when they are in the general community.
- There is a high prevalence of BBVs, especially <u>hepatitis C</u>, among people in custodial settings.

Infection	Consideration
<u>Chlamydia</u>	Consider self-collection of samples for testing.
<u>Gonorrhoea</u>	Consider self-collection of samples for testing. If NAAT test result is positive, take swab at relevant site(s) for culture, before treatment.
HIV	Repeat human immunodeficiency virus (<u>HIV</u>) testing 45 days after the patient's most recent <u>HIV</u> exposure if the patient was potentially exposed within 45 days before the initial test (window period).

Testing advice

<u>Syphilis</u>	<u>Syphilis</u> is increasingly prevalent among <u>Aboriginal and Torres Strait Islander</u> <u>people</u> . As this population makes up a disproportionately high percentage of prison entrants, <u>syphilis</u> screening should be considered.
<u>Hepatitis A</u>	Vaccinate if not immune (if available).
<u>Hepatitis B (</u> HBV)	Vaccinate if not immune. Serological testing after <u>HBV</u> vaccination should be considered in custodial settings, to check <u>HBV</u> surface antibody level.
<u>Hepatitis C</u> (HCV)	Confirm <u>HCV</u> status for all people reporting a history of incarceration or <u>injecting</u> <u>drug use</u> . If <u>HCV</u> antibody positive, test for <u>HCV</u> RNA to determine if the patient has chronic <u>HCV</u> . Offer annual <u>HCV</u> testing to patients who continue to inject drugs, due to the risk of (re)infection. Curative direct-acting antivirals (DAAs) are now available as a highly effective and well-tolerated treatment.

NAAT - Nucleic Acid Amplification Test

Specimen collection guidance

Clinician collected | Self-collection

Clinical indicators for testing

- All people should be offered screening for <u>STI</u>s and BBV infections on admission to prison, and regularly throughout their incarceration period, by appropriately trained staff.
- All incarcerated people should be able to access advice and screening for <u>STI</u>s and BBV infections.
- It is not recommended to routinely test for <u>herpes</u> and <u>genital warts</u> with serology.

Special considerations

Pregnancy test where appropriate.

Follow-up

If testing results are positive, refer to <u>STI</u> management section for advice:

<u>Chlamydia</u>

- Gonorrhoea
- Hepatitis A
- Hepatitis B
- <u>Hepatitis C</u>
- <u>HIV</u>
- Syphilis

Offer contact tracing for any person diagnosed with an <u>STI</u> or BBV infection.

Anyone diagnosed with a chronic infection (e.g. <u>HIV</u>, <u>HBV</u>, <u>HCV</u>) should be linked to care as soon as possible, with treatment commenced while in custody whenever possible.

Even if all test results are negative, use the opportunity to:

- Educate about safer sex practices and harm reduction practices including condoms, lubricants, bleaching agents for needles, and pre- and postexposure prophylaxis against <u>HIV</u>, and explore how to support incarcerated patients to access these harm reduction strategies.
- Vaccinate for hepatitis <u>A</u> and <u>B</u>, if susceptible and vaccines available.
- People diagnosed with an <u>STI</u> on initial screening, or who have ongoing risk factors, should be advised to have ongoing 3-monthly screening for <u>STI</u>s and <u>HIV</u>.
- People with ongoing risk factors for <u>HCV</u> should be advised to have ongoing <u>HCV</u> screening, either 6-, or 12-monthly depending on their level of risk.

Auditable Outcomes

- 100% of people tested for STIs and blood borne virus infections in first week of admission to prison.
- 100% of people positive for an STI or BBV infection are appropriately managed.

Resources

 ASHM Sexual History Taking Video resource catalogue – People in custodial settings **Endorsement:** These guidelines have been endorsed by the Blood Borne Viruses and Sexually Transmitted Infections Standing Committee (BBVSS).

Developed by: the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) ABN 48 264 545 457 | CFN 17788

Funded by: The Australian Government Department of Health

Disclaimer: Whilst the Australian Department of Health provides financial assistance to ASHM, the material contained in this resource produced by ASHM should not be taken to represent the views of the Australian Department of Health. The content of this resource is the sole responsibility of ASHM. <u>www.ashm.org.au</u>